Top

European Journal of Nutrition

Published in:

Open Access 02-02-2023 | Obesity | Original Contribution

Anti-obesity effects of Lactiplantibacillus plantarum SKO-001 in high-fat diet-induced obese mice

Authors: Mi Jin Choi, Hana Yu, Jea Il Kim, Hee Seo, Ju Gyeong Kim, Seul-Ki Kim, Hak Sung Lee, Hyae Gyeong Cheon

Published in: European Journal of Nutrition | Issue 4/2023

Abstract

Purpose

Previous reports showed that some probiotics provide beneficial effects on various diseases including metabolic disorders. This study aimed to investigate the anti-obesity effects of Lactiplantibacillus (L.) plantarum SKO-001 (SKO-001), a probiotic strain newly isolated from Angelica gigas.

Methods

C57BL/6J mice were fed with high-fat diet (HFD, 60% fat) for four weeks, and then different doses of SKO-001 (n = 10 each group) were orally given for 12 weeks. Following treatment, body weight, fat weight, serum parameters and adipose and liver tissues were analyzed.

Results

SKO-001 (2 × 10¹⁰ CFU/day, per os) reduced body weight gain after 10th week of administration, accompanied by a reduction in body fat mass of mice. In the SKO-001-fed group, increased serum adiponectin, decreased leptin, insulin, total cholesterol, low-density lipoprotein cholesterol, free fatty acids, and triglyceride levels were observed. Hematoxylin and eosin staining of various fat depots showed that increased adipocyte size caused by HFD intake was markedly reduced and correlated with reduced mRNA levels of lipogenesis genes, including sterol regulatory element-binding protein-1c, peroxisome proliferator-activated receptor gamma, and CCAAT/enhancer binding protein alpha, and increased uncoupling protein 1 levels. Similarly, SKO-001 reduced lipid accumulation, decreased the mRNA levels of lipogenic genes, and reduced α-smooth muscle actin and collagen type 1 alpha 1 levels in the liver.

Conclusions

SKO-001 ameliorates obesity and related metabolic abnormalities in adipose and liver tissues, possibly via the regulation of lipid metabolism. Based on the results of the present study, SKO-001 may be applicable as an anti-obesity therapeutic or functional food.

Available only for authorised users

Keller KB, Lemberg L (2003) Obesity and the metabolic syndrome. Am J Crit Care 12:167–170 (PMID: 12615276)CrossRefPubMed

Grundy SM (2004) Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89:2595–2600. https://doi.org/10.1210/jc.2004-0372CrossRefPubMed

Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101:15718–15723. https://doi.org/10.1073/pnas.0407076101CrossRefPubMedPubMedCentral

Dixon JB, le Roux CW, Rubino F, Zimmet P (2012) Bariatric surgery for type 2 diabetes. Lancet 379:2300–2311. https://doi.org/10.1016/S0140-6736(12)60401-2CrossRefPubMed

Srivastava G, Apovian C (2018) Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Curr Obes Rep 7:147–161. https://doi.org/10.1007/s13679-018-0300-4CrossRefPubMed

Tang C, Kong L, Shan M, Lu Z, Lu Y (2021) Protective and ameliorating effects of probiotics against diet-induced obesity: A review. Food Res Int 147: 110490. https://doi.org/10.1016/j.foodres.2021.110490

Coelho M, Oliveira T, Fernandes R (2013) Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci 9:191–200. https://doi.org/10.5114/aoms.2013.33181CrossRefPubMedPubMedCentral

Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clinical Endo Metabolism 89:2548–2556. https://doi.org/10.1210/jc.2004-0395CrossRef

Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, Beguinot F, Miele C (2019) Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci 20:2358. https://doi.org/10.3390/ijms20092358CrossRefPubMedPubMedCentral

10.

Poher AL, Veyrat-Durebex C, Altirriba J, Montetn X, Colin DJ, Caillon A, Lyautey J, Jeanrenaud FR (2015) Ectopic UCP1 overexpression in white adipose tissue improves insulin sensitivity in Lou/C rats, a model of obesity resistance. Diabetes 64:3700–3712. https://doi.org/10.2337/db15-0210CrossRefPubMed

11.

Petruzzelli M, Schweiger M, Schreiber R, Campos-Olivas R, Tsoli M, Allen J, Swarbrick M, Rose-John S, Rincon M, Robertson G (2014) A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia. Cell Metab 20: 433–447. https://doi.org/10.1016/j.cmet.2014.06.011

12.

Kim SH, Plutzky J (2016) Brown fat and browning for the treatment of obesity and related metabolic disorders. Diabetes Metab J 40:12–21. https://doi.org/10.4093/dmj.2016.40.1.12CrossRefPubMedPubMedCentral

13.

Lomonaco R, Sunny NE, Bril F, Cusi K (2013) Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 73: 1–14. https://doi.org/10.1007/s40265-012-0004-0

14.

Marra F, Svegliati-Baroni G (2018) Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 68:280–295. https://doi.org/10.1016/j.hep.2017.11.014CrossRefPubMed

15.

Zhang CY, Yuan WG, He P, Lei JH, Wang CX (2016) Liver fibrosis and hepatic stellate cells: etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol 22:10512–10522. https://doi.org/10.3748/wjg.v22.i48.10512CrossRefPubMedPubMedCentral

16.

Pedersen TA, Bereshchenki O, Garcia-Silva S, Ermakova O, Kurz E, Mandrup S, Porce BT, Nerlov C (2007) Distinct C/EBPa motifs regulate lipogenic and gluconeogenic gene expression in vivo. EMBO J 26:1081–1093. https://doi.org/10.1038/sj.emboj.7601563CrossRefPubMedPubMedCentral

17.

Ferre P, Foufelle F (2007) SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res 68:72–82. https://doi.org/10.1159/000100426CrossRefPubMed

18.

Tang C, Lu Z (2019) Health promoting activities of probiotics. J Food Biochem 43: e12944. https://doi.org/10.1111/jfbc.12944

19.

Kobyliak N, Conte C, Cammarota G, Haley AP, Styriak I, Gaspar L, Fusek J, Rodrigo L, Kruzliak P (2016) Probiotics in prevention and treatment of obesity: a critical view. Nutr Metab 13:14. https://doi.org/10.1186/s12986-016-0067-0CrossRef

20.

Li Y, Liu T, Zhang X, Zhao M, Zhang H, Feng F (2019) Lactobacillus plantarum helps to suppress body weight gain, improve serum lipid profile and ameliorate low-grade inflammation in mice administered with glycerol monolaurate. J Func Foods 53:54–61. https://doi.org/10.1016/j.jff.2019.12.015CrossRef

21.

Wu CC, Weng WL, Lai WL, Tsai HP, Liu WH, Lee MH, Tsai YC (2015) Effect of Lactobacillus Plantarum strain K21 on high fat diet-fed obese mice. Evid Based Complement Alternat Med 391767. https://doi.org/10.1155/2015/391767

22.

Choi WJ, Dong HJ, Jeong HU, Ryu DW, Song SM, Kim YR, Jung HH, Kim TH, Kim YH (2020) Lactobacillus plantarum LMT1–48 exerts anti-obesity effect in high-fat diet-induced obese mice by regulating expression of lipogenic genes. Sci Rep 10: 869. https://doi.org/10.1038/s41598-020-57615-5

23.

Rahayu ES, Mariyatun M, Manurung NEP, Hasan PN, Therdtatha P, Mishima R, Komalasari H, Mahfuzah NA, Pamungkaningtyas FH, Yoga WK (2021) Effect of probiotic Lactobacillus plantarum Dad-13 powder consumption on the gut microbiota and intestinal health of overweight adults. World J Gastroenterol 27: 107–128. https://doi.org/10.3748/wjg.v27.i1.107

24.

Barathikannan K, Chelliah R, Rubab M, Daliri EBM, Elahi F, Kim DH, Agastian P, Oh SY, Oh DH (2019) Gut microbiome modulation based on probiotic application for anti-obesity: a review on efficacy and validation. Microorganisms 7: 456. https://doi.org/10.3390/microorganisms7100456

25.

Ji Y, Chung YM, Park S, Jeong D, Kim B, Holzapfel WH (2019) Dose-dependent and strain-dependent anti-obesity effects of Lactobacillus sakei in a diet induced obese murine model. Peer J 7: e6651. https://doi.org/10.7717/peerj.6551

26.

Karimi G, Sabran MR, Jamaluddin RJ (2015) The anti-obesity effects of Lactobacillus casei strain Shirota versus Orlistat on high fat diet-induced obese rats. Food Nutr Res 59:29273. https://doi.org/10.3402/fnr/.v59.29273CrossRefPubMed

27.

Kang JH, Yun SI, Park MH, Park JH, Jeong PA, Park HO (2013) Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. Plos One 8: e54617. https://doi.org/10.1371/journal.pone.0054617

28.

Shoelson SE, Lee J, Yuan M (2003) Inflammation and the IKKb/IkB/NF-kB axis in obesity- and diet-induced IR. Int J Obes Relat Metab Disord 27: S49-S52. https://doi.org/10.1038/sj.ijo.0802501

29.

Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597–609. https://doi.org/10.1016/s1097-2765(00)80210-5CrossRefPubMed

30.

Jones JR, Barrick C, Kim KA, Lindner J, Blondeau B, Fujimoto Y, Shiota M, Kesterson RA, Kahn BB, Magnuson MA (2005) Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci USA 102:6207–6212. https://doi.org/10.1073/pnas.0306743102CrossRefPubMedPubMedCentral

31.

Ribot J, Rantala M, Kesaniemi VA, Palou A, Savolainen MJ (2001) Weight loss reduces expression of SREBP1c/ADD1 and PPARgamma2 in adipose tissue of obese women. Pflugers Arch 441:498–505. https://doi.org/10.1007/s004240000454CrossRefPubMed

32.

Park YJ, Seo DW, Gil TY, Cominguez DC, Lee H, Lee DS, Han I, An HJ (2020) Pharmacological properties of a traditional Korean formula Bojungchiseup-tang on 3T3-L1 preadipocytes and hifh-fat diet-induced obesity mouse model. Biomed Res Int 2020:8851010. https://doi.org/10.1155/2020/8851010CrossRefPubMedPubMedCentral

33.

Miller SG, Vos PD, Guerre-Millo M, Wong E, Herman T, Staels B, Briggs MR, Auwerx J (1996) The adipocyte specific transcription factor C/EBPa modulates human ob gene expression. Proc Natl Acad Sci USA 93:5507–5511. https://doi.org/10.1073/pnas.93.11.5507CrossRefPubMedPubMedCentral

34.

Carr MC, Brunzell JD (2004) Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89:2601–2607. https://doi.org/10.1210/jc.2004-0432CrossRefPubMed

35.

Chen S, Ren Z, Huo Y, Yang W, Peng L, Lv H, Nie L, Wei H, Wan C (2022) Targeting the gut microbiota to investigate the mechanism of Lactiplantibacillus plantarum 1201 in negating colitis aggravated by a high-salt diet. Food Res Int 162 (PtA): 112010. https://doi.org/10.1016/j.foodres.2022.112010

36.

Soundharrajan I, Kuppusamy P, Srisesharam S, Lee JC, Sivanesan R, Kim D, Choi KC (2020) Positive metabolic effects of selected probiotic bacteria on diet-induced obesity in mice are associated with improvement of dysbiotic gut microbiota. FASEB J 34:12289–12307. https://doi.org/10.1096/fj.202000971RCrossRefPubMed

37.

Tnag C, Meng F, Pang X, Chen M, Zhou L, Lu Z, Lu Y (2020) Protective effects of Lactobacillus acidophilus NX2–6 against oleic acid-induced steatosis, mitochondrial dysfunction, endoplasmic reticulum stress and inflammatory responses. J Funct Foods 74: 104206. https://doi.org/10.1016/j.jff2020.104206

Title: Anti-obesity effects of Lactiplantibacillus plantarum SKO-001 in high-fat diet-induced obese mice
Authors: Mi Jin Choi
Hana Yu
Jea Il Kim
Hee Seo
Ju Gyeong Kim
Seul-Ki Kim
Hak Sung Lee
Hyae Gyeong Cheon
Publication date: 02-02-2023
Publisher: Springer Berlin Heidelberg
Keywords: Obesity
Obesity
Probiotics
Insulins
Insulins
Published in: European Journal of Nutrition / Issue 4/2023
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-023-03096-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2023

Load and muscle group size influence the ergogenic effect of acute caffeine intake in muscular strength, power and endurance

Diet quality, food intake and incident adult-onset asthma: a Lifelines Cohort Study

Dietary patterns and young adult body mass change: A 9-year longitudinal study

Skeletal muscle and erythrocyte redox status is associated with dietary cysteine intake and physical fitness in healthy young physically active men

Association between dietary patterns and carotid intima-media thickness: cross-sectional analysis of ELSA-Brasil study

Prospective cohort study on potato intake and mortality from cardiovascular diseases: the Japan Collaborative Cohort Study (JACC study)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials